Tiffany Chen
GenVec(US)Boston Biomedical (United States)(US)
Publications by Year
Research Areas
Streptococcal Infections and Treatments, COVID-19 Clinical Research Studies, SARS-CoV-2 and COVID-19 Research, Antimicrobial Resistance in Staphylococcus, CAR-T cell therapy research
Most-Cited Works
- → A worldwide population of Streptococcus pyogenes strains circulating among school-aged children in Auckland, New Zealand: a genomic epidemiology analysis(2023)19 cited
- → Charting elimination in the pandemic: a SARS-CoV-2 serosurvey of blood donors in New Zealand(2021)11 cited
- → Naturally acquired functional antibody responses to group A Streptococcus differ between major strain types(2023)7 cited
- → SUN-556 GNTI-122: A Potentially Curative Engineered Treg Cell Therapy for the Treatment of Recently Diagnosed Type 1 Diabetes(2025)
- → A Worldwide Population of <i>Streptococcus Pyogenes</i> Strains Circulating Among School-Aged Children in Auckland, New Zealand: A Genomic Epidemiology Analysis(2023)
- → Engineered Tissue Tregs ameliorate inflammatory and ischemic diseases 3661(2025)
- → CAR19 EngTregs offer broad capacity to modulate immune tolerance and improve safety in B and T cell mediated autoimmune disorders 3850(2025)
- → Adoptive transfer of allogeneic murine Engineered Regulatory T cells ameliorates disease in models of ischemic stroke and acute lung injury 3688(2025)